ライフサイエンスコーパス: placebo-controlled trial

1 reduce symptoms of patients in a randomized placebo-controlled trial.

2 cteristics of CTS in women taking an AI in a placebo-controlled trial.

3 This was a double-blind, placebo-controlled trial.

4 RISA) 004 study, a double-blind, randomized, placebo-controlled trial.

5 recruited into this double-blind randomized placebo-controlled trial.

6 was reported in a double-blind, randomized, placebo-controlled trial.

7 has not been substantiated by a randomised, placebo-controlled trial.

8 hy, we conducted a randomized, double-blind, placebo-controlled trial.

9 were randomly assigned in a double-blinded, placebo-controlled trial.

10 a multicenter, randomized (1:1 allocation), placebo-controlled trial.

11 a pre-registered, randomised, double-blind, placebo-controlled trial.

12 y.This study was a randomized, double-blind, placebo-controlled trial.

13 presentation in a prospective, double blind, placebo-controlled trial.

14 evaluated in two multicenter, double-blind, placebo-controlled trials.

15 We did two randomised, double-blind, placebo-controlled trials.

16 ally affect interpretation of the results of placebo-controlled trials.

17 umab may be examined in larger double-blind, placebo-controlled trials.

18 In this double-blind, placebo-controlled trial, 120 asymptomatic Plasmodium fa

19 In this randomized, blinded, parallel-group, placebo-controlled trial, 150 subjects (age 67 +/- 9 yea

20 In this randomized, double-blind, placebo-controlled trial, 18- to 50-year-olds received 2

21 In a randomised double-blind, placebo controlled trial, 22 early onset PD patients, we

22 We identified 252 placebo-controlled trials (26 324 patients on placebo) d

23 his single-centre, randomised, double blind, placebo-controlled trial, 31 patients with aSAH were ran

24 In a randomised, double-blind, placebo-controlled trial, 40 HIV-infected participants w

25 In this 2 x 2 factorial, double-blind placebo-controlled trial, 457 lead-exposed Moroccan chil

26 In this randomized, double-blind, placebo-controlled trial, 50 patients with biopsy-proven

27 In a multicenter, double-blind, randomized, placebo-controlled trial, 62 patients were allocated to

28 tive, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients were randomiz

29 is international, multicentre, double-blind, placebo-controlled trial, adult patients (>/=18 years) w

30 his single-centre, randomised, double-blind, placebo-controlled trial, adult patients (aged 18 years

31 this multicentre, randomised, double-blind, placebo-controlled trial, adults (>/=18 years) with S au

32 In this randomized, placebo-controlled trial, adults with newly diagnosed or

33 In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a

34 ducted a 2-year, randomized, double-blinded, placebo-controlled trial among 2727 households in 3 nort

35 herpes zoster in a randomized, double-blind, placebo-controlled trial among 3408 persons coinfected w

36 tland Coronary Prevention Study) randomized, placebo-controlled trial, and observational posttrial lo

37 s a multi-centric, double-blind, randomized, placebo- controlled trial applying two single doses of O

38 This exploratory, randomized, double-blind, placebo-controlled trial assessed a preemptive antifunga

39 This randomized, double-blind, placebo-controlled trial assessed the effects of tenapan

40 We did this randomised, parallel-group, placebo-controlled trial at 46 secondary care centres in

41 In this randomised, double-blind, placebo-controlled trial at 590 sites in 42 countries, w

42 Double-blinded, placebo-controlled trial at 9 academic medical centers i

43 e, randomised, double-blind, parallel-group, placebo-controlled trial at Glenfield Hospital (Leiceste

44 We did a randomised, double-blind, placebo-controlled trial at three centres in the USA and

45 y cohort, we did a double-blind, randomised, placebo-controlled trial based in Doneguebougou and surr

46 We did this randomised, double-blind, placebo-controlled trial between Dec 15, 2009, and Oct 2

47 In this randomised, double-blind, placebo-controlled trial, boys from three centres in the

48 med our study as a randomized, double-blind, placebo-controlled trial by training other subjects in a

49 In the placebo-controlled trial, clinical remission was defined

50 This multicenter, double-blind, placebo-controlled trial compared the effects of intrave

51 et Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30 versus 12 months o

52 ODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing 150 million bone marr

53 We conducted a double-blinded, randomized, placebo-controlled trial comparing daily TMP-SMX plus mo

54 al, multicenter, randomized, double-blinded, placebo-controlled trial comparing extended (30-months)

55 re included in the randomized, double-blind, placebo-controlled trial, comprising 3 years of treatmen

56 participants in a randomized, double-blind, placebo-controlled trial conducted at 11 clinical center

57 Phase 3, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 12 cou

58 k, randomized, double-blind, parallel-group, placebo-controlled trial conducted at three academic med

59 this prospective, double-blind, randomized, placebo-controlled trial conducted at two tertiary care

60 Double-blind, randomized, placebo-controlled trial conducted between August 2011 a

61 Multicenter, randomized, double-blind, placebo-controlled trial conducted between May 2010 and

62 In a double-blind, placebo-controlled trial conducted from 1998 through 200

63 Randomized, double-blind, placebo-controlled trial conducted in 13 French cardiac

64 uction Trial was a randomized, double-blind, placebo-controlled trial conducted in 3 centers across t

65 Multicenter, randomized, double-blind, placebo-controlled trial conducted in 3 Spanish teaching

66 se 3, multicenter, randomized, double-blind, placebo-controlled trial conducted in 720 hospitals in 2

67 In a randomized, double-blind, placebo-controlled trial conducted in Europe, we assigne

68 A randomized, double-blind, multisite placebo-controlled trial conducted in human subjects dem

69 h Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Ug

70 Randomized placebo-controlled trial conducted October 2011 through

71 R criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to

72 ed case-control study and a small randomized placebo-controlled trial demonstrating beneficial effect

73 t 1 consisted of a randomised, double-blind, placebo-controlled trial done over 18 months.

74 Two international, randomized, double-blind, placebo-controlled trials (DUAL-1, DUAL-2) were conducte

75 A randomized, double-blind, placebo-controlled trial (Effects of Psychotropic Drugs

76 For this phase 3, parallel, randomised, placebo-controlled trial, eligible patients were adults

77 In this first randomized, double-blind, placebo-controlled trial, enoxaparin (40 mg once daily)

78 Randomized, double-blinded, placebo-controlled trial enrolled 31 patients with recur

79 METHODS AND Randomized, double-blinded, placebo-controlled trial enrolled 31 patients with recur

80 Double-blind, randomized, placebo-controlled trial, enrolling 92 participants with

81 is highlights the need for more high-quality placebo-controlled trials, equipoise may no longer be gu

82 30 placebo-controlled trials evaluated epidural corticoster

83 ntically designed, randomized, double-blind, placebo-controlled trials evaluated the efficacy of bude

84 Methods In the MAP.3 randomized, placebo-controlled trial evaluating exemestane, particip

85 This is the first randomized placebo-controlled trial evaluating the novel coadminist

86 We identified all randomized, placebo-controlled trials evaluating fluconazole prophyl

87 The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRI

88 conducted a 16-week randomized double-blind placebo-controlled trial for geriatric depression in 143

89 was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruit

90 Placebo-controlled trials for cognitive impairment assoc

91 Pooled data from randomized, double-blind, placebo-controlled trials for the clinical development p

92 Randomized, placebo-controlled trial from July 2014 to May 2016.

93 ncluding drug tapers, drug-free periods, and placebo-controlled trials, had a low risk of symptom exa

94 ntraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function

95 are observational although some randomised, placebo-controlled trials have been conducted with omega

96 e used routinely to treat depression, yet no placebo-controlled trials have been published in this po

97 Randomised placebo-controlled trials have shown that daily oral pre

98 ollowing up these findings in a double-blind placebo controlled trial in nondiabetic heart failure (t

99 nducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers across North Amer

100 We undertook this randomised, double-blind, placebo-controlled trial in a general adult intensive ca

101 We did this randomised, double-blind, placebo-controlled trial in antenatal clinics at 15 Nati

102 In a previously described randomised, placebo-controlled trial in Dhaka, Bangladesh, we showed

103 We did this multicentre, randomised, placebo-controlled trial in four centres in Kenya.

104 Double-blind, placebo-controlled trial in HIV+ with CD4(+) T cells/mic

105 terventions, describe evidence from a recent placebo-controlled trial in India suggesting that contro

106 onducted a cluster-randomized, double-blind, placebo-controlled trial in Indonesia and assigned 954 h

107 We conducted a randomized, placebo-controlled trial in Niger to evaluate the effica

108 In a double-blind, placebo-controlled trial in Niger, we randomly assigned

109 udy consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chroni

110 hase 2 double-blind, multicentre, randomised placebo-controlled trial in previously untreated adult p

111 ased, individually randomised, double-blind, placebo-controlled trial in the Brong Ahafo region of Gh

112 We did this randomised, double-blind, placebo-controlled trial in two tertiary-care hospitals

113 ydants study was a randomized, double-blind, placebo-controlled trial in which participants received

114 ed a multi-center, double-blind, randomized, placebo-controlled trial in which smokers hospitalized w

115 We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative i

116 We report two double-blind, randomised, placebo-controlled trials in adults with chronic non-can

117 Placebo-controlled trials in drug-free patients have lon

118 The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerb

119 onducted to identify double-blind randomized placebo-controlled trials in schizophrenia or related di

120 We reanalyzed 2 double-blind, placebo-controlled trials in unmedicated middle-aged men

121 a challenge to design rigorous, randomized, placebo-controlled trials, in part owing to problems of

122 This randomized, placebo-controlled trial included 4- to 6-month-old infa

123 THOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizoph

124 Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with sta

125 We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with

126 We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with at

127 In a randomized, double-blind, placebo-controlled trial involving 84,496 adults 65 year

128 We performed a randomized, double-blind, placebo-controlled trial involving human immunodeficienc

129 ted a multicenter, randomized, double-blind, placebo-controlled trial involving patients in whom peri

130 metabolic alkalosis, but no large randomized placebo-controlled trial is available to confirm this ap

131 No placebo-controlled trials met inclusion criteria, eviden

132 week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo

133 undertook a phase I double-blind, randomized placebo controlled trial of vaccination with AERAS-402 f

134 re search in MEDLNE and included randomized, placebo controlled trials of RAAS inhibitors in chronic

135 We performed a single-center, double-blind, placebo-controlled trial of 2 separate cohorts (March 20

136 We performed a prospective, double-blind, placebo-controlled trial of 449 consecutive patients und

137 s), we performed a randomized, double-blind, placebo-controlled trial of 5 days of 80 mg lovastatin v

138 gle site, we did a randomised, double-blind, placebo-controlled trial of a monovalent influenza A H1N

139 nducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring conta

140 a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (

141 n ongoing phase 2, randomised, double-blind, placebo-controlled trial of a TDV is being done at three

142 e, double-blind, randomised, parallel-group, placebo-controlled trial of A1PI treatment in patients w

143 med a prospective, randomized, double-blind, placebo-controlled trial of adults with eosinophilic eso

144 We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilo

145 nine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a stati

146 rollment within the context of a randomized, placebo-controlled trial of an investigational agent for

147 e of exception from informed consent in this placebo-controlled trial of an investigational agent was

148 ere we report on a randomized, double-blind, placebo-controlled trial of an oral synbiotic preparatio

149 We performed a randomized, double-blind, placebo-controlled trial of anastrozole in patients with

150 the Physicians' Health Study, a randomized, placebo-controlled trial of aspirin and beta-carotene am

151 G) participated in a randomised double-blind placebo-controlled trial of blood- plus liver-stage drug

152 We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patien

153 lled in a randomized, 3-month double-masked, placebo-controlled trial of daily 2 g DHA or placebo cap

154 ata from women in the Partners PrEP Study, a placebo-controlled trial of daily oral PrEP (either teno

155 is of the Partners PrEP Study, a randomized, placebo-controlled trial of daily oral TDF, alone or wit

156 We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of n

157 MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before

158 tients with UC who participated in a phase 2 placebo-controlled trial of etrolizumab, as well as from

159 In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin t

160 We performed a proof of concept, placebo-controlled trial of extended-release phentermine

161 bstudy of iPrEx, a randomized, double-blind, placebo-controlled trial of FTC/TDF PrEP.

162 (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy volunteers aged 50-8

163 arting antiretroviral therapy (ART) during a placebo-controlled trial of HSV-2 suppression with acycl

164 Healthy adults participating in a randomized placebo-controlled trial of inactivated (IIV) and live-a

165 t participants (age range, 18-49 years) in a placebo-controlled trial of inactivated influenza vaccin

166 id an individually randomised, double-blind, placebo-controlled trial of infants born in the Morogoro

167 MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs nor

168 No large, randomized, placebo-controlled trial of iodine supplementation in pr

169 Randomised placebo-controlled trial of low-dose and high-dose fish

170 ngs from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantami

171 We conducted a double-blind, randomized, placebo-controlled trial of MMS in 17- to 45-y-old Gambi

172 ible for a nested, randomised, double-blind, placebo-controlled trial of MVA-BN-Filo.

173 t baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in whic

174 In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination wi

175 rteen-week, randomized, double-blind, 3-arm, placebo-controlled trial of participants meeting DSM-IV-

176 n an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic s

177 aseline and at multiple time points during a placebo-controlled trial of peanut OIT and SLIT.

178 rvention After Stroke trial, a double-blind, placebo-controlled trial of pioglitazone for secondary p

179 e Parents (ECAP) were tested in a randomized placebo-controlled trial of pre-emptive high-dose flutic

180 key psychometric properties in a randomized placebo-controlled trial of pre-emptive high-dose flutic

181 part of a parallel-design, block-randomized, placebo-controlled trial of preconception LDA.

182 We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with

183 ts, we conducted a randomized, double-blind, placebo-controlled trial of supplementation with vitamin

184 n 3381 HIV/HSV-2-coinfected individuals in a placebo-controlled trial of suppressive acyclovir therap

185 We did a double-blind, randomised, placebo-controlled trial of the effect of azithromycin o

186 This was a multisite randomized double-blind placebo-controlled trial of ultra-low-dose sublingual bu

187 We did a double-blind, randomised, placebo-controlled trial of vaginal progesterone, 200 mg

188 We conducted a randomized, placebo-controlled trial of valganciclovir therapy in ne

189 re enrolled in a randomized, double-blinded, placebo-controlled trial of vitamin D supplementation du

190 l-conducted large, randomized, double-blind, placebo-controlled trial of vitamin D supplementation fo

191 We did a randomised, double-blind, placebo-controlled trial of vitamin D3 supplementation i

192 s P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26,449 patients

193 IMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in patients with s

194 s P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in stable patients

195 on 54) (ticagrelor) were blinded, randomized placebo-controlled trials of antiplatelet therapy for th

196 shed and unpublished double-blind randomised placebo-controlled trials of first-generation and second

197 rom two phase III, randomized, double-blind, placebo-controlled trials of IFN-gamma-1b in idiopathic

198 on: Few studies of acute gout treatments, no placebo-controlled trials of management of hyperuricemia

199 his review analyzed randomized double-blind, placebo-controlled trials of molecularly targeted therap

200 Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-generation antidepre

201 d two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants conta

202 Data from randomized, double-blind, placebo-controlled trials of Timothy grass SLIT-tablet M

203 ted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adul

204 We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influ

205 as been clearly demonstrated, a double-blind placebo-controlled trial on the effect of low-molecular-

206 In a multicenter, double-blind, placebo-controlled trial, participants presenting with a

207 In this phase III, double-blind, placebo-controlled trial, patients with chemotherapy-nai

208 Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive ea

209 his single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkins

210 ture clinical research should focus on large placebo-controlled trials, powered for perinatal outcome

211 In this randomised, placebo-controlled trial, pregnant women in Bangalore, I

212 nance imaging to a randomized, double-blind, placebo-controlled trial (RCT) of antidepressant medicat

213 Previously, we demonstrated in a randomized, placebo-controlled trial (RCT) that these infections can

214 This randomized, double-blind, placebo-controlled trial recruited patients aged 18 to 7

215 This double-blind, randomised, placebo-controlled trial recruited patients from seven U

216 d even higher protection against HIV than in placebo-controlled trials, refuting concerns that effect

217 ERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) represents the largest study o

218 In two consecutive placebo-controlled trials (SET and RESET), we assessed s

219 found in all four much smaller, randomized, placebo-controlled trials specifically designed to evalu

220 lth Study II was a randomized, double-blind, placebo-controlled trial testing multivitamin use (multi

221 ept study (POC) was an 8-week, double-blind, placebo-controlled trial that evaluated LY2940094 as a n

222 rial (SCUT) was a randomized, double-masked, placebo-controlled trial that overall found no effect of

223 rapy to Lower Cardiovascular Events trial, a placebo-controlled trial that randomized 3883 hemodialys

224 was a multicenter, double-blind, randomized, placebo-controlled trial that randomly assigned patients

225 essment Study is a randomized, double-blind, placebo-controlled trial that recruited participants mos

226 was a multicentre, double-blind, randomised, placebo-controlled trial that recruited pregnant women f

227 We used a 4-way randomized, crossover, placebo-controlled trial that was balanced for period an

228 In this randomized, placebo-controlled trial (the Bortezomib in Late Antibod

229 In a randomized, double-blind, placebo-controlled trial (the Dietary Intervention, Stem

230 to corticosteroids in COPD in a randomized, placebo-controlled trial, the Groningen and Leiden Unive

231 We conducted a randomized, placebo-controlled trial to assess daily treatment with

232 We conducted a double-blind, placebo-controlled trial to assess the effect of the ext

233 This was a 12-week randomized, placebo-controlled trial to assess the efficacy of queti

234 The authors conducted a double-blind placebo-controlled trial to assess whether high-dose ora

235 ed a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and s

236 We performed a randomized placebo-controlled trial to determine the long-term effi

237 We performed a randomized, double-blind, placebo-controlled trial to determine whether a combinat

238 We performed a double-blind, randomized, placebo-controlled trial to determine whether co-adminis

239 We conducted a double-blind, placebo-controlled trial to evaluate the effect of granu

240 We performed a randomized, double-blind, placebo-controlled trial to evaluate the effects of anti

241 ormed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and sa

242 We performed a double-blind, placebo-controlled trial to evaluate the efficacy of par

243 rom 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the efficacy of tre

244 We performed a double-blind, randomized, placebo-controlled trial to examine whether GTCs protect

245 s conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of

246 ps, we conducted a double-blind, randomized, placebo-controlled trial to investigate whether vitamin

247 This is the first randomised placebo-controlled trial to show preservation of the vis

248 e is enough equipoise to justify randomized, placebo-controlled trials to determine if nonparaneoplas

249 e is enough equipoise to justify randomized, placebo-controlled trials to determine whether patients

250 REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital diabe

251 In this double-blind, placebo-controlled trial, undertaken across three UK Nat

252 ase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel com

253 ering B vitamins on brain atrophy rates in a placebo-controlled trial (VITACOG).

254 A randomized double-blind, placebo-controlled trial was conducted in 1104 healthy s

255 This multicenter, randomized, placebo-controlled trial was conducted in 30 patients wi

256 A double-blinded, randomized, placebo-controlled trial was conducted to assess the nee

257 This phase 2, randomised, double-blind, placebo-controlled trial was done in 72 baranguays (vill

258 This double-blind, randomised, placebo-controlled trial was done in 90 international ce

259 A randomized, double-blind, placebo-controlled trial was performed in 16 ICUs in sev

260 A randomized, single-blinded, placebo-controlled trial was performed on 25 subjects: 1

261 A phase 3, randomized, double-blind, placebo-controlled trial was performed to evaluate the s

262 The aim of this randomized placebo-controlled trial was to determine if withdrawing

263 This phase 3, double-blind, placebo-controlled trial was undertaken at 101 internati

264 This multicentre, randomised, double-blind, placebo-controlled trial was undertaken at 39 sites (mos

265 this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the efficacy and s

266 In a multicenter, randomized, double-blind, placebo-controlled trial, we compared alefacept (two 12-

267 In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezep

268 In a prospective, randomized, double-blind, placebo-controlled trial, we enrolled patients with atri

269 In this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newl

270 For this double-blind, randomised, placebo-controlled trial, we enrolled self-referred or p

271 In this phase 4, randomised, placebo-controlled trial, we enrolled two consecutive se

272 In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patien

273 In a placebo-controlled trial, we found that the probiotic BL

274 In a double-blind, randomized, placebo-controlled trial, we investigated the effect of

275 In this randomized, double-blind, placebo-controlled trial, we investigated the effect of

276 In a phase 2, double-blind, placebo-controlled trial, we randomized 63 nonosteoporot

277 In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 57 (

278 ntre phase 1b, first-in-human, single-blind, placebo-controlled trial, we randomly assigned (1:1) hea

279 In this double-blind, placebo-controlled trial, we randomly assigned 120 child

280 In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 wome

281 In this double-blind, placebo-controlled trial, we randomly assigned 558 hyper

282 n this phase III, multicenter, double-blind, placebo-controlled trial, we randomly assigned patients

283 In this double-blind, placebo-controlled trial, we randomly assigned pregnant

284 In this double-blind, randomized, placebo-controlled trial, we recruited adult patients wi

285 For this multicentre, randomised, placebo-controlled trial, we recruited adults (aged 18-6

286 In this randomised, double-blind, placebo-controlled trial, we recruited patients aged at

287 In this phase 3, double-blind, placebo-controlled trial, we recruited patients with pro

288 In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had bee

289 lot prospective, randomized, double-blinded, placebo-controlled trial, we studied whether 14 days of

290 n a preregistered, randomized, double-blind, placebo-controlled trial, we tested the effect of a sing

291 Two randomized, placebo-controlled trials were performed with 168 flaviv

292 udy and an integrated analysis based on five placebo-controlled trials were summarized.

293 o determine, in a multicenter double-blinded placebo-controlled trial, whether maximal hepatic arteri

294 study, data were pooled from two randomized, placebo-controlled trials, which were originally designe

295 We performed a randomized, double-blind, placebo-controlled trial with a 12-week baseline period

296 We thus performed a randomized placebo-controlled trial with atorvastatin 40 mg/day for

297 We now report that in a double-blind, placebo-controlled trial with healthy participants, acut

298 KCC) trial was a randomized, double-blinded, placebo-controlled trial with patients from dermatology

299 This was a double-blind, placebo-controlled trial with subjects randomized to oma

300 quantified by comparing simulated randomised placebo-controlled trials within the out-of-sample LABS-